






PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)


Applicant's or agent's file reference 3040WOOP	FOR FURTHER ACTION		cation of Transmittal of International Examination Report (Form PCT/IPEA/416)
International application No. PCT/JP2003/004554	International filing date (day/n 10 April 2003 (10.04	•	Priority date (day/month/year) 12 April 2002 (12.04.2002)
International Patent Classification (IPC) or A61K 45/00, 31/519, A61P 5/2			
Applicant TA	KEDA CHEMICAL INDU	ISTRIES, L	TD.
and is transmitted to the applicant at 2. This REPORT consists of a total of This report is also accomparamended and are the basis for 70.16 and Section 607 of the These annexes consist of a total of This report contains indications relating to These annexes consist of a total of This report contains indications relating to These annexes consist of a total of This report is also accomparamented and are the basis for This report is als	sheets, including the sheets, including the sheets, including the sheets of this report and/or sheets contains and the sheets contains and the sheets. The sheets of this report and/or sheets contains and the sheets contains and the sheets. The sheets of this report and/or sheets contains and the sheets. The sheets of the sheets of the sheets of the sheets of the sheets. The sheets of the	g this cover so the descriptioning rectificater the PCT).	on, claims and/or drawings which have been tions made before this Authority (see Rule
Date of submission of the demand 09 May 2003 (09.05.		completion of 23 Fe	of this report Ebruary 2004 (23.02.2004)
Name and mailing address of the IPEA/JP	Author	ized officer	
Facsimile No.	Telepho	one No.	





		of the re	
1. V	Vith		to the elements of the international application:*
Ď	X	the inte	ternational application as originally filed
		the des	scription:
	_	pages	, the originality most
		pages	, filed with the demand
	•	pages	
	丁	the clai	
_	_	pages	, as originally filed
		pages	, as amended (together with any statement under Article 19
		pages	, filed with the demand
ı		pages	, filed with the letter of
Г	\neg	the drav	
_	_	pages	
		pages	, as originally filed, filed with the demand
		pages	, filed with the letter of, med with the demand
Г	_		
<u>_</u>	-		ence listing part of the description:
		pages pages	, as originally filed
		pages pages	, filed with the demand
-		,	, filed with the letter of
tn	ne int	iternation	to the language, all the elements marked above were available or furnished to this Authority in the language in which anal application was filed, unless otherwise indicated under this item. ats were available or furnished to this Authority in the following language which is:
Ĺ			nguage of a translation furnished for the purposes of international search (under Rule 23.1(b)).
Ļ			aguage of publication of the international application (under Rule 48.3(b)).
L		the lang	nguage of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/3).
3. W	/ith relin	шпагу ех	to any nucleotide and/or amino acid sequence disclosed in the international application, the international examination was carried out on the basis of the sequence listing:
F	4		ned in the international application in written form.
F	_		ogether with the international application in computer readable form.
Ļ	_	-	ned subsequently to this Authority in written form.
F	_		ned subsequently to this Authority in computer readable form.
L		internat	tatement that the subsequently furnished written sequence listing does not go beyond the disclosure in the ational application as filed has been furnished.
L	Ţ	The sta been fu	atement that the information recorded in computer readable form is identical to the written sequence listing has urnished.
4. []	The am	nendments have resulted in the cancellation of:
	_ [the description, pages
	Γ		the claims, Nos.
	ſ		the drawings, sheets/fig
5. [] ;	This repo	port has been established as if (some of) the amendments had not been made, since they have been considered to go the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**
uu	place this	cement sh report	sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16)
ana	a 70.	<i>J.17)</i> .	ent sheet containing such amendments must be referred to under item 1 and annexed to this report.





III. Non-	establishment of opinion with regard to novelty, inventive step and industrial applicability
1. The condust	questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be trially applicable have not been examined in respect of:
	the entire international application.
\boxtimes	claims Nos7
becaus	
	the said international application, or the said claims Nos
Se	ee supplemental sheet
	the description, claims or drawings (indicate particular elements below) or said claims Nosare so unclear that no meaningful opinion could be formed (specify):
	·
	the claims, or said claims Nos are so inadequately supported by the description that no meaningful opinion could be formed.
\boxtimes	no international search report has been established for said claims Nos
sequenc	ningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid ce listing to comply with the standard provided for in Annex C of the Administrative Instructions: the written form has not been furnished or does not comply with the standard.
	the computer readable form has not been furnished or does not comply with the standard.



Internal application No. PCT/JP 03/04554

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: III. 1.

Claim 7 pertains to methods for treatment of the human body by therapy, and thus relates to subject matter which does not require international preliminary examination by this International Preliminary Examining Authority, under the provisions of PCT Article 34(4)(a)(i) and PCT Rule 67.1(iv).

V.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
	citations and explanations supporting such statement

citations and explanations supporting such statement				
•	Statement			
	Novelty (N)	Claims	1-6, 8	YES
		Claims		NO
	Inventive step (IS)	Claims		YES
		Claims	1-6, 8	NO
	Industrial applicability (IA)	Claims	1-6, 8	YES
		Claims		NO

2. Citations and explanations

Claims 1-6 and 8

Document 1: WO 99/55358 A
Document 2: WO 00/56739 A

The inventions set forth in claims 1-6 and 8 do not involve an inventive step in the light of document 1 and document 2, cited in the international search report. The compounds disclosed in document 2 have an outstanding GnRH antagonist action and, therefore, a person skilled in the art could easily conceive of using a compound disclosed in document 2 as an LHRH antagonist disclosed in document 1.